AMD

RAMQ is a public organization introduced in 1970, following the adoption of the universal health care system in Canada.

Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia under the terms of the agreement.

The Portal study is a long-term extension of the phase 3 Archway study

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD.

KIO-104 is for the treatment of a wide range of ocular diseases, including ocular inflammation, uveitis, age-related macular degeneration (AMD), and complications as a result of refractive surgery.

Australian researchers highlighted the overlooked ocular risks surfers and divers face from UV and blue light exposure.

President Joel S. Schuman, MD, highlights the group’s mission and vision for the future—uniting 17 working groups and over 80 stakeholders.

Jim Mazzo is among the presenters who will highlight the need to break silos and accelerate eye health solutions at the Collaborative Community on Ophthalmic Innovation (CCOI) meeting at Stanford University on July 23, 2025.

Included in the agreement are ranibizumab-nuna 0.05 mL injection (BYOOVIZ), referencing LUCENTIS (ranibizumab), and aflibercept-yszy 0.05 mL injection (OPUVIZ), referencing EYLEA (aflibercept).

KAIST researchers unveil a new microbial strain for efficient, eco-friendly lutein production.

Preliminary results of PST-611-CT1 are anticipated early 2026, subject to patient recruitment.

The company notes that the workforce reduction is expected to provide annual cash compensation cost savings of approximately $15 million and offsets additional expenses expected based on the accelerated timelines for the 4FRONT clinical trials.

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.

A new study links urinary metabolites from organophosphorus pesticides to increased age-related macular degeneration risk.

Yesafili is the first biosimilar to Eylea to be approved by Health Canada.

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients

FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema, macular edema following retinal vein occlusion, and visual impairment due to myopic choroidal neovascularization.

Ixo-vec shows sustained efficacy and reduces injection burden through 4 years in clinical trials

Changing demographics and increasing trial complexity present challenges and opportunities.

To conduct the study, the investigators obtained data on coffee consumption from genome‐wide association studies (GWAS) and the latest AMD‐related GWAS summary data from the Finngen consortium R11.

With detailed imaging and cognitive data, the Northern Ireland Cohort for the Longitudinal Study of Aging highlights the potential of integrating eye scans into broader health research.

Optical coherence tomography markers—like the ellipsoid zone—are reshaping clinical trials in intermediate age-related macular degeneration, as highlighted at the 2025 International SPECTRALIS Symposium — And Beyond (ISS).